Prognostic significance of HER2-low and HER2-zero status before and after neoadjuvant chemotherapy in patients with HER2-negative breast cancer.

ABSTRACT:

Background

Changes in human epidermal growth factor receptor 2 (HER2) status following neoadjuvant chemotherapy (NAC) indicate tumor heterogeneity.

Objective

Investigating the prognostic impact of the transition between HER2-low and HER2-zero may help eliminate the confounding effects of heterogeneity, thereby clarifying the prognostic significance of HER2-low status.

Design

Retrospective analysis.

Methods

Data were collected from patients with HER2-negative, early-stage breast cancer who did not achieve a pathological complete response after NAC. Cox regression models and Kaplan-Meier survival curves were employed to analyze disease-free survival (DFS) and overall survival (OS).

Results

A total of 744 patients were included in the analysis, including 20

SUBMITTER: Ma Y 

PROVIDER: S-EPMC12602912 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature